XBiotech has developed a screening technology to identify SARS-CoV-2 convalescent individuals with high titer antibodies against the virus. XBiotech has transferred the technology to enable blood bank providers to identify and make SARS-CoV-2 convalescent plasma to hospitals for treating patients sick with the disease. 

The Company is also developing True Human antibody therapeutic from healthy, SARS-CoV-2 infected individuals, in other words, from individuals that had such good natural antibody responses that they neutralized the virus without contracting any significant illness. Identification of healthy convalescent donors with high titer SARS-CoV-2 antibodies with no history of severe clinical infection is a key strategy in development of our therapies. 

COVID-19 disease is associated in rare cases with an excessive inflammatory response, known as a “cytokine storm.” This can be a lethal consequence of the virus infection. Considerable scientific evidence has emerged suggesting that IL-1⍺ blockade could be effective in down regulating the inflammatory cascade associated with cytokine storm. XBiotech is aggressively developing an anti-IL-1⍺ True Human antibody product candidate that could be used as a disease modifying therapy in COVID-19.

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19